Amendments to the Claims

This listing of the claims will replace all prior versions and listing of claims in this application.

Listing of Claims

1. (Currently Amended) **A s**~~S~~olid pharmaceutical formulation comprising**:**
   - **a.** an active pharmaceutical ingredient **which is a quinolone antibiotic**,
   - **b.** **4 to 20 % by weight of** a flavo~~u~~ring **which is a mixture of proteins, fats, and carbohydrates,** and**,**
   - **c.** ~~**at least**~~ 1.5% **to 15%** by weight of colloidal silicon dioxide based on the total weight of the finished formulation **wherein the ratio by weight of colloidal silicon dioxide to flavoring is 1:4 to 1:1**.

2. (Currently Amended) **The s**~~S~~olid pharmaceutical formulation according to claim 1, ~~**comprising as active pharmaceutical ingredient**~~ **wherein the quinolone antibiotic is selected from the group consisting of** enrofloxacin, an enrofloxacin salt or a hydrate of enrofloxacin or of its salt.

3. (Currently Amended) **The s**~~S~~olid pharmaceutical formulation according to claim 1, ~~**comprising as active pharmaceutical ingredient**~~ **wherein the quinolone antibiotic is selected from the group consisting of** pradofloxacin, a pradofloxacin salt or a hydrate of pradofloxacin or of its salt.

4. (Currently Amended) **A p**~~P~~rocess for producing the solid pharmaceutical formulation according to claim 1, in which the flavo~~u~~ring is granulated with the colloidal silicon dioxide and with one or more active ingredients and pharmaceutically customary additives and/or excipients.

5. (New) A solid pharmaceutical formulation according to Claim 1, comprising a quinolone antibiotic of formula (I)



(I)

in which

A is nitrogen or =C-R^4,

R^4 is hydrogen, fluorine, chlorine, cyano, nitro or methyl,

B is



and

R^5 is hydrogen, a branched or unbranched alkyl group having 1 to 4 carbon atoms, which may optionally be substituted by a hydroxyl or methoxy group,

R^6 is hydrogen, methyl or phenyl,

R^7 is hydrogen or methyl,

R^8 is amino, alkyl- or dialkylamino having 1 or 2 carbon atoms in the alkyl group, aminomethyl, alkyl- or dialkylaminomethyl having 1 or 2 carbon atoms in the alkyl group,

R^1 is an alkyl radical having 1 to 3 carbon atoms, cyclopropyl, 2-fluoroethyl, vinyl, methoxy, 4-fluorophenyl or methylamino,

R^2 is hydrogen, alkyl having 1 to 6 carbon atoms, and cyclohexyl, benzyl, 2-oxopropyl, phenacyl and ethoxycarbonylmethyl, and

Z is oxygen, methyl- or phenyl-substituted nitrogen, and $-CH_2-$,

or a pharmaceutically usable salt thereof.

6. (New) A solid pharmaceutical formulation according to Claim 1, comprising a quinolone antibiotic of formula (II)



(II)

in which

B is



and

R^5 is hydrogen, a branched or unbranched alkyl group having 1 to 4 carbon atoms, which may optionally be substituted by a hydroxyl or methoxy group,

R^6 is hydrogen, methyl or phenyl,

R^7 is hydrogen or methyl,

R^8 is amino, alkyl- or dialkylamino having 1 or 2 carbon atoms in the alkyl group, aminomethyl, alkyl- or dialkylaminomethyl having 1 or 2 carbon atoms in the alkyl group,

R^2 is hydrogen, alkyl having 1 to 6 carbon atoms, and cyclohexyl, benzyl, 2-oxopropyl, phenacyl and ethoxycarbonylmethyl,

R^3 is hydrogen, methyl or ethyl, and

Z is oxygen, methyl- or phenyl-substituted nitrogen, and $-CH_2-$,

or a pharmaceutically usable salt thereof.

7. (New) A solid pharmaceutical formulation according to Claim 1, comprising a quinolone antibiotic of formula (Ia)



(Ia),

in which

B is



or



,

and

A is nitrogen or =C-R^4,

R^4 is hydrogen, fluorine, chlorine, cyano, nitro or methyl,

R^5 is hydrogen, a branched or unbranched alkyl group having 1 to 4 carbon atoms, which may optionally be substituted by a hydroxyl or methoxy group,

R^6 is hydrogen, methyl or phenyl,

R^7 is hydrogen or methyl, and

R^2 is hydrogen, alkyl having 1 to 6 carbon atoms, and cyclohexyl, benzyl, 2-oxopropyl, phenacyl and ethoxycarbonylmethyl,

or a pharmaceutically usable salt thereof.

8. (New) A solid pharmaceutical formulation according to Claim 1, comprising a quinolone antibiotic of formula (Ia)



(Ia),

in which

R^2 is hydrogen, alkyl having 1 to 4 carbon atoms, and benzyl, 2-oxopropyl, phenacyl and ethoxycarbonylmethyl,

B is



R^5 is hydrogen, methyl or ethyl,

R^6 is hydrogen or methyl,

R^7 is hydrogen or methyl,

A is nitrogen or =C-R^4, and

R^4 is hydrogen, fluorine, chlorine, cyano, nitro or methyl,

or a pharmaceutically usable salt thereof.

9. (New) The solid pharmaceutical formulation according to claim 1, comprising at least 2.5% by weight silicon dioxide.

10. (New) The solid pharmaceutical formulation according to claim 1, comprising not more than 15% by weight of silicon dioxide.